330200-35-6

Upstream product

• 108-30-5 succinic acid anhydride 
• 103-45-7 acetic acid phenethyl ester 

Downstream Products

• 1197360-15-8 acetic acid 2-[4-(6-oxo-1,6-dihydro-pyridazin-3-yl)-phenyl]-ethyl ester 
• 330200-37-8 6-[4-(2-hydroxy-ethyl)-phenyl]-2H-pyridazin-3-one 
• 1197359-82-2 6-{4-[2-((R)-2-methyl-pyrrolidin-1-yl)-ethyl]-phenyl}-2H-pyridazin-3-one 
• 1197359-97-9 6-{4-[2-((R)-2-methyl-pyrrolidin-1-yl)-ethyl]-phenyl}-2-phenyl-2H-pyridazin-3-one 
• 1197359-98-0 2-(4-fluoro-phenyl)-6-{4-[2-((R)-2-methyl-pyrrolidin-1-yl)-ethyl]-phenyl}-2H-pyridazin-3-one 
• 1197359-83-3 2-(4-chloro-phenyl)-6-{4-[2-((R)-2-methyl-pyrrolidin-1-yl)-ethyl]-phenyl}-2H-pyridazin-3-one 
• 1197359-84-4 2-benzyl-6-{4-[2-((R)-2-methyl-pyrrolidin-1-yl)-ethyl]-phenyl}-2H-pyridazin-3-one 

Relevant academic research and scientific papers

Synthesis and evaluation of pyridazinone.phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity

A series of pyridazinone-phenethylamine derivatives with moderate to low nanomolar affinity for rat and human H3R are described. These analogs exhibited excellent selectivity and metabolic stability, with acceptable rat pharmacokinetic properties. In vivo, 7 and 11 demonstrated potent H3R functional antagonism in the rat dipsogenia model and robust wake-promoting activity in the rat electroencephalogram/electromyography (EEG/EMG) model.